Last A$0.83 AUD
Change Today -0.01 / -1.19%
Volume 1.1M
SPL On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 2:10 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

starpharma holdings ltd (SPL) Snapshot

Open
A$0.85
Previous Close
A$0.84
Day High
A$0.87
Day Low
A$0.83
52 Week High
08/19/13 - A$1.11
52 Week Low
06/19/14 - A$0.54
Market Cap
236.6M
Average Volume 10 Days
1.9M
EPS TTM
A$-0.03
Shares Outstanding
285.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STARPHARMA HOLDINGS LTD (SPL)

Related News

No related news articles were found.

starpharma holdings ltd (SPL) Related Businessweek News

No Related Businessweek News Found

starpharma holdings ltd (SPL) Details

Starpharma Holdings Limited researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of its topical vaginal microbicide VivaGel as a condom coating for the treatment and prevention of bacterial vaginosis, as well as for the prevention of sexually transmitted infections, including genital herpes and HIV. It is also engaged in exploring dendrimer opportunities in materials science with applications in various areas, such as cosmetics, agrochemicals, and coatings. The company was founded in 1996 and is headquartered in Melbourne, Australia.

Founded in 1996

starpharma holdings ltd (SPL) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: A$518.2K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$213.1K
Vice President of Business Development
Total Annual Compensation: A$236.2K
Vice President of Development & Regulatory Af...
Total Annual Compensation: A$220.3K
Vice President of Research
Total Annual Compensation: A$218.6K
Compensation as of Fiscal Year 2013.

starpharma holdings ltd (SPL) Key Developments

FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial to Starpharma Holdings Limited

Starpharma Holdings Limited announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel bacterial vaginosis (BV) product for the prevention of recurrent BV. The favourable SPA outcome provides a binding agreement from the FDA that the phase 3 clinical study design, endpoints, statistical analyses and other aspects of the planned studies adequately address objectives in support of a US regulatory submission for approval of the product. The granting of SPA agreement by the FDA follows the earlier agreement of the European Medicines Agency (EMA) on the design of the phase 3 studies. Starpharma will now commence its two pivotal phase 3 clinical trials of VivaGel for the prevention of recurrent BV at sites in North America, Europe and Asia. The two phase 3, double-blind, randomised, placebo-controlled trials will be identical in design and will compare the rate of BV recurrence in women using VivaGel to the rate of recurrence in women using a placebo gel during a 16 week treatment period. Approximately 600 women will be recruited into each study. This significantly reduces overall development risk for VivaGel. SPA agreement from the FDA is protected by US law and gives Starpharma certainty and confidence that the studies will support a regulatory submission for the approval of VivaGel for the prevention of recurrent BV in the US. VivaGel (SPL7013, astodrimer sodium) is a non-antibiotic agent formulated as a vaginally applied gel for prevention of BV recurrence.

Starpharma Holdings Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 07:30 AM

Starpharma Holdings Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 07:30 AM. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Speakers: Jacinth K. Fairley, Chief Executive Officer and Executive Director.

Starpharma Holdings Limited Announces Executive Changes

Starpharma Holdings Limited confirmed Mr. Peter Bartels AO will retire as Chairman as part of a planned succession. As announced in November 2013, Mr. Rob Thomas AM will succeed Mr. Bartels as Chairman, effective June 13, 2014. Mr. Thomas joined the Starpharma Board in December 2013 as Non-executive Director and Chair-Elect under the Board's ongoing succession planning and director renewal strategy. Mr. Thomas is also a member of both the Audit and Risk Committee and the Remuneration and Nomination Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPL:AU A$0.83 AUD -0.01

SPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPL.
View Industry Companies
 

Industry Analysis

SPL

Industry Average

Valuation SPL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 133.6x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 119.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STARPHARMA HOLDINGS LTD, please visit www.starpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.